KiraGen Bio has been selected as finalists for the 2024 Cohort of Nucleate's Activator Program, specifically within the Boston region, amongst 18 distinguished teams. This selection highlights KiraGen's role in pioneering CAR-T cell therapies for solid tumors, leveraging combinatorial gene editing and AI to push the boundaries of cancer treatment. The inclusion in Boston's cohort of Nucleate’s Activator Program represents a key milestone for KiraGen, providing access to critical support and networking opportunities in one of the world’s leading biotech hubs. As the program unfolds, we invite our community to stay tuned for updates on our progress and the innovative strides we're making in the program!
